STOCK TITAN

Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Enlivex (Nasdaq: ENLV) signed an agreement for a $7.5 million registered direct offering of ordinary shares or pre-funded warrants, with accompanying warrants. The combined price is $1.315 per share or $1.314 per pre-funded warrant, a 10.5% premium to the November 13, 2026 Nasdaq closing price. Ordinary warrants carry a $1.578 exercise price and a three-year term.

The initial $500,000 closing is expected around November 17, 2026, followed by ten monthly $700,000 closings from December 1, 2026 through around September 1, 2027. Subsequent funding depends on continued U.S. national exchange listing; some closings may await authorized-capital approval or registration-document availability. Enlivex expects approximately $7.5 million in gross proceeds if all closings occur, before expenses. Qualifying investors also receive conditional 5% payment rights tied to specified commercial transactions and clinical-asset dispositions.

Loading...
Loading translation...
4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Registered offering targets approximately $7.5 million gross proceeds, assuming all closings occur, before offering expenses. 4.1× market cap
  • Minor pointCombined purchase price represents a 10.5% premium to the November 13, 2026 Nasdaq closing price.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Ordinary warrant cash exercise could provide approximately $9.0 million in additional gross proceeds if exercised in full.
  • Minor pointDirect offering incurs no placement agent fees.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Shares or pre-funded warrants at $1.315 or $1.314, respectively, plus matching ordinary warrants, dilute holders.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Ordinary warrants are immediately exercisable at $1.578 and expire three years from the initial closing.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants are immediately exercisable at $0.001 per share and remain outstanding until fully exercised.
  • Minor pointSubsequent $7,000,000 funding commitment depends on continued Nasdaq or another U.S. national securities exchange listing.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Certain subsequent closings may await shareholder approval of increased authorized share capital.
3 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Any subsequent closing may be postponed if the registration statement or prospectus is unavailable.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Qualifying investors receive 5% of specified commercial-transaction payments under conditional five-year receipt and transaction-entry windows.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Qualifying investors receive 5% of specified clinical-asset disposition proceeds during the stated 24-month period, subject to required shareholder approval.

News Explained

The 5% side-payment rights apply only to investors who fund at least eight hundred fifty thousand dollars.

The Enlivex offering has not reached its expected first closing on November 17, 2026; once issued, the offered shares and shares from warrant exercises can increase the share count and reduce existing holders’ percentage ownership.

A pre-funded warrant is sold near the share price and becomes a share on exercise at the stated $0.001 price; the ordinary warrants have a $1.578 exercise price. Separate warrant proceeds would be approximately $9.0 million only if all ordinary warrants are exercised for cash, and are excluded from the expected $7.5 million offering proceeds.

The company says it will use net proceeds for clinical, regulatory, manufacturing and research and development work, potential acquisitions or in-licensing, and general corporate purposes; it has no placement-agent fee, although other offering expenses remain. Qualifying investors may also receive 5% of specified commercial receipts and proceeds from clinical-asset dispositions. The company says the final prospectus supplement and a Form 6-K will provide final offering terms and additional transaction details.

Argus 15 min delay 4 alerts
-10.92% vs previous close $1.06 last price 13.3x rel. volume Open Argus
Details

Market Reaction – ENLV

-2.0% Trough Tracked
$1.00 – $1.48 Day Range
$1.62M Mkt Cap at Last Price

On Nov 16, the day this news came out, the latest delayed price for ENLV is 10.92% below the previous close. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $1.06. Relative volume is exceptionally heavy at 13.3x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Expected gross proceeds: approximately $7.5 million Initial closing: $500,000 Subsequent monthly closings: $700,000 at each of ten closings; $7,000,000 aggregate +4 more
Expected gross proceeds
approximately $7.5 million
Assuming all closings are consummated; before offering expenses and excluding warrant exercise proceeds
Initial closing
$500,000
Expected on or about November 17, 2026, subject to customary closing conditions
Subsequent monthly closings
$700,000 at each of ten closings; $7,000,000 aggregate
Investor commitment is subject to continued listing on Nasdaq or another U.S. national securities exchange
Combined purchase price
$1.315 per ordinary share and accompanying warrant
Representing a 10.5% premium to the Nasdaq official closing price on November 13, 2026
Ordinary warrant terms
$1.578 exercise price; three-year term
Warrants are exercisable immediately upon issuance
Potential warrant proceeds
approximately $9.0 million
Additional gross proceeds if all ordinary warrants are exercised in full for cash; exercise is not assured
Investor payment participation
5%
Applies to specified commercial transaction payments and clinical-asset disposition proceeds, subject to stated conditions

Historical Context

1 past event · Latest: Oct 27
1 event
  1. Oct 27

    Nasdaq delisting

    24h Move
    +3.7%

    Nasdaq delisting notice makes current investors' continued-listing condition directly relevant to scheduled purchases.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, pre-funded warrants, shelf registration statement, prospectus supplement, +1 more
5 terms
registered direct offering financial
"in a registered direct offering, of an aggregate of $7,500,000"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
pre-funded warrants financial
"ordinary shares (or pre-funded warrants in lieu thereof)"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shelf registration statement regulatory
"pursuant to a shelf registration statement on Form F-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"by means of a prospectus supplement and accompanying base prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
securities purchase agreement financial
"entered into a securities purchase agreement with certain investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Nes-Ziona, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with certain investors for the purchase and sale, in a registered direct offering, of an aggregate of $7,500,000 of the Company’s ordinary shares (or pre-funded warrants in lieu thereof), together with accompanying ordinary warrants to purchase up to an equal number of ordinary shares, at a combined purchase price of $1.315 per ordinary share (or $1.314 per pre-funded warrant) and accompanying ordinary warrant, representing a premium of 10.5% to the Nasdaq official closing price of the ordinary shares on November 13, 2026 (the “Registered Offering”). The ordinary warrants will have an exercise price of $1.578 per share, will be exercisable immediately upon issuance, and will expire three years from the initial closing date. The pre-funded warrants will have an exercise price of $0.001 per share, will be exercisable immediately upon issuance, and will not expire until exercised in full.

The Registered Offering will be consummated in a series of closings. At the initial closing, which is expected to occur on or about November 17, 2026, subject to the satisfaction of customary closing conditions, the investors will purchase an aggregate of $500,000 of securities. The investors have also irrevocably committed, subject only to the continued listing of the ordinary shares on Nasdaq or another U.S. national securities exchange, to purchase an additional aggregate of $700,000 of securities at each of ten subsequent monthly closings, commencing on December 1, 2026, and ending on or about September 1, 2027, for an aggregate of $7,000,000, at the same price and on the same terms as those applicable to the initial closing. Certain of the subsequent closings may be postponed until the Company’s receipt of shareholder approval of an increase in its authorized share capital, and any subsequent closing may be postponed if the Company’s registration statement or prospectus is not then available. The purchase price may be paid in U.S. dollars, USDT, or a combination thereof.

The aggregate gross proceeds to the Company from the Registered Offering are expected to be approximately $7.5 million, assuming all closings are consummated, before deducting offering expenses payable by the Company and excluding any proceeds from the exercise of the ordinary warrants. If the ordinary warrants issued in the Registered Offering are exercised in full for cash, the Company would receive additional gross proceeds of approximately $9.0 million; however, no assurance can be given that any of the ordinary warrants will be exercised. The Company intends to use the net proceeds from the Registered Offering for clinical, regulatory, manufacturing, and research and development activities; potential acquisitions and in-licensing; and other general corporate purposes. The Registered Offering is being made directly by the Company, without a placement agent, underwriter, broker or dealer, and no placement agent fees will be payable.

The ordinary shares, pre-funded warrants and ordinary warrants offered in the Registered Offering, and the ordinary shares issuable upon exercise of such warrants, are being offered by the Company pursuant to a shelf registration statement on Form F-3 (File No. 333-286956) previously filed with the Securities and Exchange Commission (the “SEC”), which became effective on May 12, 2025. The Registered Offering is being made only by means of a prospectus supplement and accompanying base prospectus that form a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the Registered Offering will be filed with the SEC and, when filed, will be available on the SEC’s website at www.sec.gov. Additional information regarding the securities described above and the terms of the transactions will be included in a Report on Form 6-K to be filed by the Company with the SEC.

In connection with the transactions, the Company has also agreed to pay to certain investors that meet a minimum subscription threshold, subject to the terms and conditions of the securities purchase agreement, (i) 5% of upfront, down, milestone and royalty payments received by the Company or its subsidiaries during the five years following execution, from license, collaboration, partnership, co-development, co-commercialization, distribution, supply and similar commercial transactions relating to its product candidates that are entered into during the period commencing upon the Company’s receipt of the full $7.5 million subscription amount and ending 24 months following the date of the securities purchase agreement, and (ii) 5% of the proceeds paid to the Company or its shareholders from any sale, exclusive license or other disposition of the Company’s clinical assets during such 24-month period, subject to any required shareholder approval. An investor’s right to receive such payments will be forfeited if it fails to fund at least $850,000 of that aggregate subscription amount under the securities purchase agreement.

Greenberg Traurig, P.A. and FISCHER (FBC & Co.) are serving as legal counsel to Enlivex.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

ABOUT ENLIVEX

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the expected timing and consummation of the initial closing and the subsequent closings of the Registered Offering; the anticipated gross proceeds from, and the intended use of proceeds of, the Registered Offering; the potential exercise of the ordinary warrants; the Company’s ability to obtain shareholder approval of an increase in its authorized share capital; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, risks related to market conditions and the satisfaction of closing conditions for the Registered Offering; the risk that one or more investors fail to fund their commitments at the subsequent closings; the risk that the required shareholder approval is not obtained on a timely basis or at all; the risk of failure to realize the anticipated benefits of the Registered Offering and the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the price and warrant terms of Enlivex's $7.5 million offering?

The combined price is $1.315 per ordinary share or $1.314 per pre-funded warrant, with accompanying ordinary warrants to purchase up to an equal number of shares. Ordinary warrants are immediately exercisable at $1.578 per share and expire three years from the initial closing. Pre-funded warrants are immediately exercisable at $0.001 per share and do not expire until fully exercised.

When will Enlivex receive funding from the registered direct offering?

The initial $500,000 closing is expected on or about November 17, 2026, subject to customary closing conditions. Ten subsequent monthly closings of $700,000 each begin December 1, 2026 and end on or about September 1, 2027. Subsequent closings depend on continued qualifying exchange listing and may face the disclosed shareholder-approval or registration-document delays.

What commercial-transaction payment rights will qualifying Enlivex investors receive?

Qualifying investors receive 5% of upfront, down, milestone and royalty payments received by Enlivex or its subsidiaries during the five years following agreement execution from specified product-candidate commercial transactions. Eligible transactions must be entered into between receipt of the full $7.5 million subscription and 24 months after the agreement date. An investor forfeits payment rights if it fails to fund at least $850,000.

What clinical-asset sale payment rights will qualifying Enlivex investors receive?

Qualifying investors receive 5% of proceeds paid to Enlivex or its shareholders from a sale, exclusive license or other disposition of its clinical assets during the 24 months following the securities purchase agreement date, subject to any required shareholder approval. An investor forfeits these rights if it fails to fund at least $850,000 under the agreement.

How can investors pay for securities in Enlivex's registered direct offering?

The purchase price may be paid in U.S. dollars, USDT, or a combination thereof.

Keep reading